RCT

line

Inclusion

treatment

total

n(status)

now

n

1

1L

AbbVie

Protocol M24-533

IRB 2025-05-004CU

• substudy 2 ,stage 2
• Left
• MSS, BRAF wt
•  Kras wt
• screening biopsy
• Biopsy 有就好(before any Tx)

• substudy 1 ,stage 2

Left side

RAS mutation

Right side

RAS wt or mutation

High dose arm;

ABBV 2.4 MG/KG(Q4W)

Panitumumab 6mg/KG(Q2W)

Foloc Acid 400mg/M2(Q2W)

5-FU 2400mg/M2(Q2W)

Low dose arm:

ABBV 2.0 MG/KG(Q4W)

Panitumumab 6mg/KG(Q2W)

Foloc Acid 400mg/M2(Q2W)

5-FU 2400mg/M2(Q2W)

Stardard arm:

Panitumumab 6mg/KG(Q2W)

Oxaliplatin 85mg/M2  (Q2W)

Foloc Acid 400mg/M2(Q2W)

5-FU 2400mg/M2(Q2W), 400 mg/M2 Bolus (醫師決定)

High dose arm;

ABBV 2.4 MG/KG(Q4W)

Bevacizumab

5mg/KG(Q2W)

Foloc Acid 400mg/M2(Q2W)

5-FU 2400mg/M2(Q2W)

Low dose arm:

ABBV 2.0 MG/KG(Q4W)

Bevacizumab

5mg/KG(Q2W)

Foloc Acid 400mg/M2(Q2W)

5-FU 2400mg/M2(Q2W)

Stardard arm:

Bevacizumab

5mg/KG(Q2W

Oxaliplatin 85mg/M2  (Q2W)

Foloc Acid 400mg/M2(Q2W)

5-FU 2400mg/M2(Q2W), 400 mg/M2 Bolus (醫師決定)

5

3

2

1L

Protocol No. SUGAN-029

IRB No. 2022-09-006

• Her-2 (+)
• MSS
• RAS wt ,  BRAF wt .
• prescreen around 3 wks

Pfizer

1.anit-EGFR

2.HER2-specific tyrosine kinase inhibitor (TKI)

6

持續

3

3

1L

Protocol No. WO42758

IRB No.  2022-12-011CU

• 一項第 I/ Ib 期全球性、 多中心開放傘狀試驗，用以評估標靶療法對轉移性大腸直癌病患子族群的安全性與療效(G12C mutation arm)
• 打過2次內 (CT +/- avasitn) ok
• MSS,BRAF wt
• If MSI-H,need received IO
• 對B/C肝沒有特別限制

• KRAS G12C inhibitors  +FOLFOX+Bevacizumab

10

1

4

2L

Protocol No. 61186372COR3002

IRB No.

2024-11-001AU

Inclusion criteria

• KRAS/NRAS/BRAF wt MSS
• If MSI-H,need received IO
• screening biopsy fresh or archival tumor,
• HBVDNA(-)
• HCVRNA(-)
• 需打過FOLFOX

    Exclusion

• HER-2(+) exclusion
• Irinotecan
• Cetuximab

Johnson and johnson

皮下注射 10 cc 60-80 kg

bispecific monoclonal antibody 

EGFR and MET antibody

5

4

5

2L and 2L+

Protocol:20250004

IRB:2026-02-005CU

1. 經組織學或細胞學確認患有轉移性或局部晚期實體腫瘤(MSIH/dMMR)

2. 至少接受過一線全身性療法(包含先前至少1線的PD-1抗體/PD-L1治療)。

3. 5年內 Tumor Slide: 20片

4. B / C 型肝炎可納入須為HBV DNA/HCV RNA nondectable

Amgen

AMG436 (WRN inhibitor)

dose level:100mg-2000mg

PO,QD

5

1

1L

BMS

Protocol CA-266-0003

IRB No. 2026-04-002AU

INCLUSION CRITERIA:

1)  Completion of adjuvant or neoadjuvant chemotherapy, there must be more than a 6-month gap (> 6 months).

2) MSS and BRAF V600E Wild-Type, all RAS ( Wild-Type or mutation)

3) Measurable lesion

4) Tumor tissue samples within 3 years (At least 15- 20 unstained slides)

EXCLUSION CRITERIA:

1) Prior malignancy active within the previous 2 years

2) Prior systemic treatment with PD1, PDL1, PDL2, CTLA4, CD137–targeting agents, other Tcell costimulatory/checkpoint therapies, or chemotherapy is not permitted.

3) excluded if HBV DNA is positive (defined as >500 IU/mL).

4) detectable HCV-RNA 

Pumitamig /FOLFOX/FOLFIRI/CAPOX

or

Bevacizumab

/FOLFOX/FOLFIRI/CAPOX

8

2

3L

Merck

Protocol No.: MS914001

IRB No. 2026-07-002CU 

納入條件

1.      轉移情境下接受不超過 2 種全身性治療方案

2.      接受過fluoropyrimidine, irinotecan, platinum agent (e.g. oxaliplatin) 的治療

3.      接受過 bevacizumab 的治療

4.      RAS/BRAF wt and left-sided tumors: anti-EGFR agent :

5.      MSI-H: immune checkpoint inhibitor

6.      BRAF V600E mutation: encorafenib and cetuximab

or encorafenib, cetuximab, and binimetinib

7.      HER-2 targeted therapy: trastuzumab plus tucatinib

8.      (neo)adjuvant therapy with PD during or within 6 months after regimen completion is considered as 1 regimen line in the metastatic setting

9.tissue slide 15 片。

10. measurable lesion or non measurable lesion

11.必須能夠吞服口服藥錠

排除條件

1.在隨機分配前< 4 週內進行過重大手術計在試驗期間需要進行重大手術。

2.無法控制的高血壓（BP 150 /100 mmHg）。

3 接受過 FTD-TPI、CEACAM5 含有 TOP1 抑制劑載荷藥物的 ADC治療。

5.HBV DNA>2000 IU/ml

Arm A Precemtabart tocentecan (Precem-TcT)    monotherapy

2.8 mg/kg

Q3W

Arm B

Precemtabart tocentecan (Precem-TcT)    monotherapy

2.8 mg/kg

Q3W

and

Bevacizumab   7.5mg/kg

Q3W

Arm C

Bevacizumab  5mg/kg

Q4W,

D1 and D15

and

Trifluridine/tipiracil (FTD-TPI)   

Q4W

D1-D5 on

D8-D12 on

D13-D28 off

9

0